201 related articles for article (PubMed ID: 38044354)
1. Stroma-associated FSTL3 is a factor of calcium channel-derived tumor fibrosis.
Li JP; Liu YJ; Yin Y; Li RN; Huang W; Zou X
Sci Rep; 2023 Dec; 13(1):21317. PubMed ID: 38044354
[TBL] [Abstract][Full Text] [Related]
2. Follistatin-Like 3 Correlates With Lymph Node Metastasis and Serves as a Biomarker of Extracellular Matrix Remodeling in Colorectal Cancer.
Yang C; Cao F; Huang S; Zheng Y
Front Immunol; 2021; 12():717505. PubMed ID: 34335633
[TBL] [Abstract][Full Text] [Related]
3. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
4. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
5. Identification of subclusters and prognostic genes based on glycolysis/gluconeogenesis in hepatocellular carcinoma.
Chen D; Aierken A; Li H; Chen R; Ren L; Wang K
Front Immunol; 2023; 14():1232390. PubMed ID: 37881434
[TBL] [Abstract][Full Text] [Related]
6. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
7. Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma.
Zhang C; Zhang W; Shui Y; Li P; Tian Z; Duan S; Wei Q
Front Immunol; 2022; 13():1001506. PubMed ID: 36405741
[TBL] [Abstract][Full Text] [Related]
8. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
Front Immunol; 2022; 13():994019. PubMed ID: 36177006
[TBL] [Abstract][Full Text] [Related]
9. A novel liver zonation phenotype-associated molecular classification of hepatocellular carcinoma.
Zhang T; Gu J; Wang X; Lu Y; Cai K; Li H; Nie Y; Chen X; Wang J
Front Immunol; 2023; 14():1140201. PubMed ID: 36936935
[TBL] [Abstract][Full Text] [Related]
10. The Effect of the Histone Chaperones HSPA8 and DEK on Tumor Immunity in Hepatocellular Carcinoma.
Yang C; Shao Y; Wang X; Wang J; Wang P; Huang C; Wang W; Wang J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768989
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma.
Dong W; Xie Y; Huang H
Front Endocrinol (Lausanne); 2022; 13():884777. PubMed ID: 35733776
[TBL] [Abstract][Full Text] [Related]
12. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
Gao B; Wang Y; Lu S
Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis and validation of SNX7 as a novel biomarker for the diagnosis, prognosis, and prediction of chemotherapy and immunotherapy response in hepatocellular carcinoma.
Chen J; Gao G; Zhang Y; Dai P; Huang Y
BMC Cancer; 2023 Sep; 23(1):899. PubMed ID: 37743471
[TBL] [Abstract][Full Text] [Related]
14. A novel medication decision gene signature predicts response to individualized therapy and prognosis outcomes in hepatocellular carcinoma patients.
Yuan J; Liu Z; Wu Z; Yan L; Yang J; Shi Y
Front Immunol; 2022; 13():990571. PubMed ID: 36275751
[TBL] [Abstract][Full Text] [Related]
15. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
16. Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy.
Wang Y; Peng B; Ning C; He S; Yang H; Mao Y; Sun L
Front Immunol; 2022; 13():966167. PubMed ID: 36304466
[TBL] [Abstract][Full Text] [Related]
17. PANoptosis-based molecular subtyping and HPAN-index predicts therapeutic response and survival in hepatocellular carcinoma.
Song F; Wang CG; Mao JZ; Wang TL; Liang XL; Hu CW; Zhang Y; Han L; Chen Z
Front Immunol; 2023; 14():1197152. PubMed ID: 37398672
[TBL] [Abstract][Full Text] [Related]
18. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
19. Establishment and Validation of a Novel Risk Score for Hepatocellular Carcinoma Based on Bile Acid and Bile Salt Metabolism-Related Genes.
Shi Q; Yuan X; Xue C; Gu X; Li L
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239939
[TBL] [Abstract][Full Text] [Related]
20. Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma.
Zhang L; Xu J; Chu X; Zhang H; Yao X; Zhang J; Guo Y
BMC Bioinformatics; 2022 Nov; 23(1):485. PubMed ID: 36384423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]